• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia.

作者信息

Saglio G, Guerrasio A, Rosso C, Zaccaria A, Tassinari A, Serra A, Rege-Cambrin G, Mazza U, Gavosto F

机构信息

Dipartimento di Scienze Biomediche e Oncologia Umana, Universitá di Torino, Italy.

出版信息

Blood. 1990 Nov 1;76(9):1819-24.

PMID:2224129
Abstract

A new and rare type of Bcr/Abl junction between exon C3 of the 3' portion of the Bcr gene and Abl exon 2 has been identified in the leukemic cells of two Ph1-positive chronic myelogenous leukemia patients in chronic phase. This is the fourth type of Bcr/Abl junction so far identified in Ph1-positive hematologic malignancies and is a consequence of an unusual breakpoint position on chromosome 22 that falls approximately 20 kb downstream of the major breakpoint cluster region (bcr) of the Bcr gene. The new hybrid mRNA is 540 base pairs (bp) longer than that expressed by the K562 cell line and could codify for a Bcr/Abl protein carrying 180 additional aminoacids with respect to the larger P210 protein so far identified. The hematologic phenotype expressed by the two patients carrying this unusual type of Bcr/Abl rearrangement does not significantly differ from that commonly seen in chronic myelogenous leukemia.

摘要

相似文献

1
New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia.
Blood. 1990 Nov 1;76(9):1819-24.
2
Establishment of a cell line with variant BCR/ABL breakpoint expressing P180BCR/ABL from late-appearing Philadelphia-positive acute biphenotypic leukemia.从晚期出现的费城染色体阳性急性双表型白血病中建立表达P180BCR/ABL的具有变异BCR/ABL断点的细胞系。
Genes Chromosomes Cancer. 1998 Nov;23(3):227-38. doi: 10.1002/(sici)1098-2264(199811)23:3<227::aid-gcc4>3.0.co;2-3.
3
Chromosomal breakpoints within the first intron of the ABL gene are nonrandom in patients with chronic myelogenous leukemia.
Blood. 1990 Aug 1;76(3):597-601.
4
Molecular characterization of a variant Ph1 translocation t(9;22;11) (q34;q11;q13) in chronic myelogenous leukemia (CML) reveals the translocation of the 3'-part of BCR gene to the chromosome band 11q13.慢性髓性白血病(CML)中一种变异的费城染色体1易位t(9;22;11) (q34;q11;q13)的分子特征显示,BCR基因的3'端部分易位至染色体带11q13。 1 费城染色体(Philadelphia chromosome,Ph)是一种特异性染色体异常,在慢性髓性白血病中常见。
Oncogene. 1993 Dec;8(12):3239-47.
5
Methylation of the major breakpoint cluster region (M-bcr) in Philadelphia-positive CML.费城染色体阳性慢性粒细胞白血病中主要断裂点簇集区(M-bcr)的甲基化
Leukemia. 1993 May;7(5):707-11.
6
BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia.经典型慢性髓系白血病中具有e19a2(c3a2)连接的BCR-ABL转录本
Blood. 1997 Apr 15;89(8):3064.
7
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.间期荧光原位杂交(FISH)与逆转录聚合酶链反应(RT-PCR)检测慢性粒细胞白血病及相关疾病中bcr-abl易位的比较分析
Am J Clin Pathol. 1998 Jan;109(1):16-23. doi: 10.1093/ajcp/109.1.16.
8
BCR-ABL rearrangements in children with Philadelphia chromosome-positive chronic myelogenous leukemia.费城染色体阳性慢性髓性白血病患儿中的BCR-ABL重排
Blood. 1991 Nov 1;78(9):2407-10.
9
The ABL-BCR fusion gene is expressed in chronic myeloid leukemia.ABL-BCR融合基因在慢性髓性白血病中表达。
Blood. 1993 Jan 1;81(1):158-65.
10
Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias.在小儿急性白血病中,9号与22号染色体断点一致累及bcr基因。
Blood. 1991 Jan 15;77(2):324-30.

引用本文的文献

1
Cytogenetic Response to Asciminib in Chronic Myeloid Leukemia With the e19a2 Micro BCR::ABL1 Transcript: A Case Report.携带e19a2微小BCR::ABL1转录本的慢性髓性白血病患者对阿斯科利尼布的细胞遗传学反应:一例报告
Cureus. 2025 May 2;17(5):e83363. doi: 10.7759/cureus.83363. eCollection 2025 May.
2
Molecular response of a patient with e19a2-positive chronic myeloid leukemia to flumatinib: a case report and literature review.一名e19a2阳性慢性髓性白血病患者对氟马替尼的分子反应:病例报告及文献综述
Front Med (Lausanne). 2025 Mar 17;12:1515002. doi: 10.3389/fmed.2025.1515002. eCollection 2025.
3
FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.
FISH 阴性 BCR::ABL1 阳性 e19a2 慢性髓性白血病:最隐匿的插入。
BMC Med Genomics. 2023 Jul 26;16(1):172. doi: 10.1186/s12920-023-01607-7.
4
Chronic myeloid leukemia: a type of MPN.慢性髓系白血病:一种骨髓增殖性肿瘤。
Blood Res. 2022 Jun 30;57(2):95-100. doi: 10.5045/br.2022.2021173. Epub 2022 May 30.
5
Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia.影响慢性髓性白血病预后的基因组机制
Cancers (Basel). 2022 Jan 26;14(3):620. doi: 10.3390/cancers14030620.
6
Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report.帕纳替尼诱导异基因造血干细胞移植后早期复发伴 T315I 突变的慢性髓性白血病患者持续深度分子缓解:病例报告。
BMC Cancer. 2018 Dec 7;18(1):1229. doi: 10.1186/s12885-018-5100-4.
7
Successful treatment with allogeneic stem cell transplantation followed by DLI and TKIs for e6a2 BCR-ABL-positive acute myeloid leukaemia: A case report and literature review.异基因干细胞移植联合供者淋巴细胞输注及酪氨酸激酶抑制剂成功治疗e6a2 BCR-ABL阳性急性髓系白血病:1例报告并文献复习
Medicine (Baltimore). 2017 Dec;96(50):e9160. doi: 10.1097/MD.0000000000009160.
8
Novel BCR-ABL1 fusion and leukemic mutations of SETBP1, PAX5, and TP53 detected by next generation sequencing in chronic myeloid leukemia.通过下一代测序在慢性髓性白血病中检测到的新型BCR-ABL1融合以及SETBP1、PAX5和TP53的白血病突变。
Cancer Biol Ther. 2016 Oct 2;17(10):1003-1009. doi: 10.1080/15384047.2016.1219821. Epub 2016 Sep 10.
9
A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia.通过下一代测序在慢性髓性白血病中鉴定出一种新型BCR-ABL1融合基因。
Mol Cytogenet. 2016 Jun 27;9:47. doi: 10.1186/s13039-016-0257-5. eCollection 2016.
10
Neutrophilic-chronic myeloid leukemia: A case report.中性粒细胞性慢性髓系白血病:一例报告。
Int J Health Sci (Qassim). 2015 Jan;9(1):87-90.